Accessory hepatic vein stenting to treat primary Budd-Chiari syndrome
10.3760/cma.j.issn.1007-8118.2017.10.002
- VernacularTitle:副肝静脉支架置入治疗布加综合征的疗效
- Author:
Zhi QI
1
;
Qingqiao ZHANG
;
Hao XU
;
Maoheng ZU
;
Yuming GU
;
Hongtao LIU
;
Zhikang GAO
;
Xun WANG
;
Duntao LV
;
Qianxin HUANG
Author Information
1. 221006,徐州医科大学附属医院介入放射科
- Keywords:
Budd-Chiari syndrome;
Accessory hepatic vein;
Stent placement
- From:
Chinese Journal of Hepatobiliary Surgery
2017;23(10):655-658
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the safety and efficacy of accessory hepatic vein (AHV) stenting to treat primary Budd-Chiari syndrome (BCS).Methods The clinical data of 20 BCS patients with AHV ostial stenosis or occlusion were retrospectively analyzed.These 20 patients underwent balloon dilation and AHV stenting.Thirteen patients underwent AHV stenting via the right jugular vein approach,5 patients via the right femoral vein approach,and 2 patients via the percutaneous transhepatic combined with the right femoral vein approach.On follow-up,patency of the AHV stent was evaluated by color Doppler ultrasound.The cumulative primary and secondary patency rates were assessed with the Kaplan-Meier curves.Results AHV stenting was successful in 20 patients.Angiography showed that the AHV was patent after stenting.The mean pressure gradient between the AHV and the inferior vena cava reduced from (19.2 ± 4.8) cmH2O (1 cmH2O =0.098 kPa) before treatment to (4.5 ± 1.9) cmH2O after treatment (t =7.119,P ＜ 0.01).During the procedure,rupture of the AHV caused by balloon dilation occurred in one patient.This was treated successfully by a covered stent placement.On follow-up from 1 to 80 months [(32.1 ±27.4) months]after treatment for the 20 patients,re-stenosis of the AHV were found in 5 patients.They were treated successfully with re-dilation.The cumulative 1-,3-,and 5-year primary patency rates were 100％,85.1％ and 74.5％,respectively.The cumulative 1-,3-,and 5-year secondary patency rates were 100％,90.9％ and 90.9％,respectively.One patient died of hepatic failure 3 years after the treatment.Conclusion AHV stenting was a safe and efficacious treatment for BCS and it provided good mid-and long-term results.
